Analyst firms · H.C. Wainwright · AKRO

H.C. Wainwright AKRO price target and rating history

Akero Therapeutics Inc. (AKRO) · Health Care

H.C. Wainwright rates Akero Therapeutics Inc. (AKRO) Buy with a $72 price target, as of its latest action on Sep 4, 2025. It has published 4 rating actions on AKRO since August 2021, including 0 upgrades and 0 downgrades.

Current rating

Buy

Price target

$72

Median target, all firms

Too few

Actions on AKRO

4

H.C. Wainwright price target on AKRO

Every H.C. Wainwright rating on AKRO

• Sep 4, 2025
  ResumeH.C. Wainwright resumes coverage at Buy, price target $72
• Jan 27, 2025
  ReiterateH.C. Wainwright raises its price target to $72 from $50, keeps Buy
• Nov 15, 2021
  ReiterateH.C. Wainwright cuts its price target to $62 from $64, keeps Buy
• Aug 16, 2021
  ReiterateH.C. Wainwright cuts its price target to $64 from $68, keeps Buy

Questions about H.C. Wainwright and AKRO

What is H.C. Wainwright's price target for AKRO?

H.C. Wainwright's latest stated price target for Akero Therapeutics Inc. (AKRO) is $72, from its action on Sep 4, 2025.

What is H.C. Wainwright's rating on AKRO?

H.C. Wainwright rates AKRO Buy, a bullish rating, as of Sep 4, 2025.

When did H.C. Wainwright last change its view on AKRO?

On Sep 4, 2025, H.C. Wainwright resumes coverage at Buy, price target $72.

More AKRO rating histories

• BofA Securities3
• Morgan Stanley3

All H.C. Wainwright ratingsAKRO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.